ACAD Earnings
Latest Revenue308.0M
Latest Net Income31.5M
| Period | EPS | Revenue | Net Income | Rev YoY | EPS YoY |
|---|
| Q2 2026 | $0.18 | 308.0M | 31.5M | +16.4% | +12.5% |
| Q1 2026 | $0.02 | 268.1M | 3.6M | +9.7% | -81.8% |
| Q4 2025 | $1.61 | 284.0M | 273.6M | +9.4% | +87.2% |
| Q3 2025 | $0.43 | 278.6M | 71.8M | +11.3% | +115.0% |
| Q2 2025 | $0.16 | 264.6M | 26.7M | +9.3% | -20.0% |
| Q1 2025 | $0.11 | 244.3M | 19.0M | +18.7% | +10.0% |
| Q4 2024 | $0.86 | 259.6M | 143.7M | +12.4% | +207.1% |
| Q3 2024 | $0.20 | 250.4M | 32.8M | +18.3% | +150.0% |
| Q2 2024 | $0.20 | 242.0M | 33.4M | — | — |
| Q1 2024 | $0.10 | 205.8M | 16.6M | — | — |
| Q4 2023 | $0.28 | 231.0M | 45.8M | — | — |
| Q3 2023 | -$0.40 | 211.7M | -65176000 | — | — |
Acadia Pharmaceuticals (ACAD) — Earnings